NEW YORK (GenomeWeb News) – The Icahn School of Medicine at Mt. Sinai and biopharmaceutical firm Berg today announced a five-year partnership aimed at cancer, as well as central nervous system and endocrine disorders.
The agreement will take a multi-omics and big data analytical approach to gain insight into the three disease areas in order to potentially develop therapeutics and diagnostic tools, the partners said.